NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia Co-Founder Prof. Dr. Laura vanโt Veer Honored at Three Prestigious Breast Cancer Symposia in Italy, the Netherlands and the U.S. for Pioneering Work in Breast Cancer Diagnostics
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS, November 14, 2024 - Prof. Dr. Laura van 't Veer, co-founder of Agendia, pioneer in personalized cancer care and co-developer of the MammaPrintยฎ genomic breast cancer recurrence test, Read More
Agendia’s FLEX Study Reaches Enrollment of Over 17,000 Early-Stage Breast Cancer Patients Across Diverse Population
This achievement highlights the remarkable seven-year progression of FLEX and its many sub-studies highlighting the ethnic and racial nuances that may influence treatment pathways. IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ September 12, 2024 Read More
Agendia Achieves CE-IVDR Certification
Agendia Achieves CE-IVDR Certification for its MammaPrint and BluePrint Breast Cancer Assays
Read MoreNewsroom
News, Stories & Breast Cancer Blog
Improved RFS Seen with Anthracycline Plus Chemo in MP High-2โRisk, HR+/HER2โ Early Breast Cancer
By Ryan Scottย June 1, 2024 A lower risk of disease recurrence was seen when combining anthracycline and chemotherapy to treat certain patients with breast cancer. Anthracycline plus a taxane and cyclophosphamide was linked to Read More
Coffee with America: Dr. William Audeh for Agendia Breast Cancer Subtyping
Discover why understanding the specific characteristics of breast cancer is crucial for developing personalized treatment strategies that can significantly improve outcomes. Dr. William Audeh, a leading medical oncologist specializing in breast cancer and Agendia Read More
Genomic Testing Transforms Breast Cancer Care and Treatment Success
In an insightful interview with Dr. William Audeh, MD, MS, Chief Medical Officer at Agendia, featured in ONCOLife, we explore the pioneering strides in genomic testing within breast cancer treatment. Dr. Audeh, shares his Read More
Recognizing Common Breast Cancer Symptoms & the Importance of Early Detection
Breast cancer is the most common cancer among women, with about 1 in 8 women being diagnosed in their lifetime.[1] It also accounts for nearly 30% of all new female cancer diagnoses each year, with Read More
Faith Over Fear, My Life Matters (Winter 2023-2024)
A journey to inclusive breast cancer care through faith, science, and personalized testing.
Read the ArticleArticle: Disparities in Survival Outcomes Revealed w/ BluePrint + MammaPrint
โThese data highlight the importance of genomic testing to help optimize treatment and reduce outcome disparities in Black women.โ
Read the ArticleAgendia Touting New Data Showing Pre-Surgery Use of MammaPrint, BluePrint
Research showing that Agendia's MammaPrint and BluePrint tests can predict which breast cancer patients are likely to have the cancer in their lymph nodes down-staged following neoadjuvant chemotherapy has the company optimistic about a potentially new use for its gene expression tests.
Read the Article
